·Ñ³ÇȾɫÌå,Philadelphia chromosomeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±ÐÔµ¥ºËϸ°û°×Ѫ²¡,acute monocytic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ATM»ùÒò,ATM geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« COX»Ø¹éÄ£ÐÍ,COX regression modelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Smac»ùÒò,Smac GeneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÆÏÌÑÌÇÉñ¾­õ£°·ºÏ³Éø,glucosylceramide synthaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ki67»ùÒò,Ki67 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Æµ÷ËØÞ׿¹¼Á,Calmodulin antagonistÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃÖÂþ´óBϸ°ûÁܰÍÁö,diffuse large B-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²¸È鶯ÎïÀ×ÅÁÃ¹ËØ°Ðµ°°×,mammalian target of rapamycinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±ÐÔ·ÇÁܰÍϸ°û°×Ѫ²¡,acute non-lymphocytic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃâÒ߹̶¨µçÓ¾,Immunofixation electrophoresisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­°©»ùÒòµ°°×ÖÊc-myc,proto-oncogene proteins c-mycÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³¤ÆÚÉú´æ,Long-term survivalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏÔÏñ¼Á,imaging agentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« FAB·ÖÐÍ,FAB classificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ì×ϸ°ûÁܰÍÁö,Mantle cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« As_2O_3,arsenic trioxideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Ç»ôÆæ½ð/Ò©ÎïÁÆ·¨,non-Hodgkin/drug therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HL-60ϸ°ûϵ,HL-60 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Tϸ°ûÁܰÍÁö,T-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« NB4ϸ°ûÖê,NB4 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« WesternÓ¡¼£·¨,Western blottingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÜÆÚµ°°×E,cyclin EÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Áò»¯Éé,Arsenic SulfideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐÎ̬²ÎÊý,morphological parametersÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂýÐÔ°×Ѫ²¡,chronic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 1ºÅȾɫÌå,Chromosome 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂýÐÔËèÐÔ°×Ѫ²¡,chronic myeloid leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Æ¥Åä¸ÅÂÊ,matching probabilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³¬Î¢Èõ·¢¹â,Ultraweak luminescenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« U266ϸ°û,U266 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢С²ÐÁô²¡Ôî,minimal residual diseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éÖ¯Òò×Ó;¾¶ÒÖÖÆÎï-2,tissue factor pathway inhibitor-2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ëèϵ°×Ѫ²¡,myeloid leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« BurkittÁܰÍÁö,Burkitt lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Ö×ÓÏÔÏñ,Molecular imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« L5178Yϸ°û,L5178Y cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ȾɫÌåÏÔ´ø,chromosome bandingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °ëë×°±ËáÄÚëÄøÀà,Cysteine endopeptidasesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×é֯ѧÀàÐÍ,histological typeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁܰÍÁöϸ°û,Lymphoma cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ùͯ°×Ѫ²¡,Childhood leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇËèÁöϸ°û,myeloma cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÎÞ²¡Éú´æ,disease-free survivalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûоƬ,cell microarrayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁܰÍÁöÑùÈâÑ¿Öײ¡,lymphomatoid granulomatosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢Á¿²ÐÁô²¡,Minimal residual diseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔìѪϸ°ûÉú³¤Òò×Ó,Hematopoietic cell growth factorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« NKϸ°ûÊÜÌå,NK cell receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MIC·ÖÐÍ,MIC classificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±ÐÔÔçÓ×Á£Ï¸°ûÐÔ°×Ѫ²¡,acute promyelocytic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ä±äÐÔÁܰÍÁö¼¤Ã¸,anaplastic lymphoma kinaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« K562/ADMϸ°û,K562/ADM cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« BCR/ABL»ùÒò,BCR/ABL geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ÔÌåÍâÖÜѪÔìѪ¸Éϸ°ûÒÆÖ²,autologous peripheral blood stem cell transplantationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÖÆÚϵͳ,staging systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃâÒßÇòµ°°×ÖØÁ´,immunoglobulin heavy chainÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢С²ÐÁô²¡±ä,minimal residual diseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« PhȾɫÌå,Ph chromosomeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Ö×ÓÑÇÐÍ,molecular subtypeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« BP1»ùÒò,BP1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂãÊóÄ£ÐÍ,Nude mice modelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇËè¼äÖÊϸ°û,bone marrow stromal cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 8ºÅȾɫÌå,Chromosome 8Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« µç»¯Ñ§DNAÉúÎï´«¸ÐÆ÷,electrochemical DNA biosensorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Á£Ï¸°ûÈâÁö,Granulocytic sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Livinµ°°×,Livin proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µªÀ¶ËÄßò,nitroblue tetrazoliumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²¡ÀíÑ§ÌØÕ÷,pathological featureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« P53ͨ·,P53 pathwayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °×Ѫ²¡Ï¸°ûϵ,leukemic cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Òì»ùÒòÍâÖÜѪÔìѪ¸Éϸ°ûÒÆÖ²,Allogeneic peripheral blood stem cell transplantationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Æ¢ÔàÖ×Áö,splenic neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« K562/ADMϸ°ûÖê,K562/ADM cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ð¤Ä¤Ïà¹ØÁܰÍÑù×éÖ¯,Mucosa-associated lymphoid tissueÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈËIL-24,Human IL-24Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ôÆæ½ð²¡,Hodgkin diseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ùͯ¼±ÐÔÁܰÍϸ°û°×Ѫ²¡,childhood acute lymphoblastic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Rad51»ùÒò,Rad51 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼äÆÚÓ«¹âԭλÔÓ½»,interphase fluorescence in situ hybridizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« AML1/ETOÈںϻùÒò,AML1/ETO fusion geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« bcl-6»ùÒò,bcl-6 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éé¼Á/ÖÎÁÆÓ¦ÓÃ,arsenicals/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·´Òå¹ÑºËÜÕËáÀà,antisense oligonucleotidesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Bcl-2»ùÒò¼Ò×å,Bcl-2 gene familyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« tkλµã,tk geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Òì»ùÒòÒÆÖ²,Allogeneic transplantationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« B7»ùÒò,B7 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Bimµ°°×,Bim proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« VAD·½°¸,VAD regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²®»ùÌØÁܰÍÁö,Burkitt lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û±íÃæ¿¹Ô­,cell surface antigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö»µËÀÒò×ÓÏà¹ØµÄµòÍöÓÕµ¼ÅäÌå,TRAILÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ZO-1»ùÒò,ZO-1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ó¡½äϸ°û°©,Signet-ring cell carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« BCRP»ùÒò,BCRP geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ùͯÐÄÀí,Children PsychologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« CEMϸ°û,CEM cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ãÎ÷µØÇø,Guangxi regionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«